London-based Autolus, a biopharmaceutical company focused on developing and commercializing T-cell therapies, has raised about $150 million after pricing 8.8 million shares of its IPO at $17 per share. The stock began trading June 22, 2018 on the NASDAQ under the ticker symbol “AUTL.” Goldman Sachs and Jefferies LLC are the lead underwriters. Autolus’pre-IPO backers include Arix Bioscience plc, Cormorant Asset Management, Nextech Invest, Syncona and Woodford Investment Management.
London, 22 June 2018 – Autolus Therapeutics plc (“Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of its initial public offering in the United States of 8,823,530 American Depositary Shares (“ADSs”) representing 8,823,530 ordinary shares at an initial public offering price of $17.00 per ADS for total gross proceeds of approximately $150.0 million. All ADSs sold in the offering were offered by Autolus. The ADSs are expected to begin trading on The Nasdaq Global Select Market on June 22, 2018 under the ticker symbol “AUTL.” In addition, Autolus has granted the underwriters a 30-day option to purchase up to an additional 1,323,529 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on June 26, 2018, subject to customary closing conditions.
Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.
The offering will be made only by means of a prospectus. When available, copies of the final prospectus related to the offering can be obtained from either of the joint book-running managers for the offering, Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at +1 866 471 2526 or by email at email@example.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by email at Prospectus_Department@Jefferies.com or by telephone at + 1 877 821 7388. For the avoidance of doubt, such prospectus will not constitute a “prospectus” for the purposes of Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in each relevant EU member state) and will not have been reviewed by any competent authority in any EU member state.
A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the “SEC”). Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.